Re: While we wait, outside items that may be of interest

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: While we wait, outside items that may be of interest

in response to

While we wait, outside items that may be of interest

imtesty

posted on Aug 23, 2017 01:00PM

Imtesty,

Yes, the presentations at ESC on the REVEAL (CETP inhibitor anacetrapib) and the CANTOS (anti-inflammatory Canakinumab antibody) cardiovascular outcomes trials will be very interesting. So far only top-line data has been released for these two trials. Although we know that these two trials met their primary endpoints for reducing MACE, we won't know the magnitude of the effect until the ESC presentatons. Merck's comments in the news release of top-line REVEAL data conveyed some doubt as to whether they were going to pursue filing an NDA for anacetrapib. We will know more of the story soon enough.